Carolina Lanza, Salvatore Alessio Angileri, Pierpaolo Biondetti, Andrea Coppola, Francesco Ricapito, Velio Ascenti, Gaetano Amato, Giuseppe Pellegrino, Lucilla Violetta Sciacqua, Andrea Vanzulli, Serena Carriero, Massimo Venturini, Anna Maria Ierardi, Gianpaolo Carrafiello
{"title":"经皮微波消融治疗肝癌：100 W 和 150 W 技术系统的比较。","authors":"Carolina Lanza, Salvatore Alessio Angileri, Pierpaolo Biondetti, Andrea Coppola, Francesco Ricapito, Velio Ascenti, Gaetano Amato, Giuseppe Pellegrino, Lucilla Violetta Sciacqua, Andrea Vanzulli, Serena Carriero, Massimo Venturini, Anna Maria Ierardi, Gianpaolo Carrafiello","doi":"10.1007/s11547-024-01927-3","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the differences in efficacy and safety between the 100 and 150 W percutaneous microwave ablation (MWA) systems in the treatment of hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>We retrospectively reviewed all patients who underwent percutaneous MWA (Emprint™ HP Ablation System, Medtronic) between January 2021 and May 2023. We divided the cohort into two groups: Group 1, treated with MWA at 100 W power system, and Group 2, treated with 150 W one. Effectiveness was defined as the absence of residual disease at 1-month CT follow-up; safety was defined as the absence of grade II-VI complications.</p><p><strong>Results: </strong>A total of 135 HCC nodules were treated with MWA in 87 patients with a median age of 66 ± 10 years: 76 procedures in 42 patients were carried out in group 1, while 59 procedures in 45 patients in group 2. Cases treated with 150 W had a shorter ablation time (p: 0.002; mean 227.37 ± 92.5 vs 180.51 ± 75.6 s (100 vs 150 W)) and a larger ablation volume (p 0.008; mean 13,920.0 ± 10,723.2 vs 21,241.4 ± 18,374.7 mm<sup>3</sup> (100 vs 150 W)), and a major effectiveness at 1-month CT follow-up (p: 0.013). A higher rate of complications (grade II and III) was observed in Group 2 (p < 0.001).</p><p><strong>Conclusions: </strong>In conclusion, these preliminary results showed a good correlation between intended-to-treat area and ablation volume and intended-to-treat area and ablation time for both Groups. A minor ablation time, and major ablation volume, but also a higher incidence of complications was observed in 150 W Group.</p>","PeriodicalId":20817,"journal":{"name":"Radiologia Medica","volume":" ","pages":""},"PeriodicalIF":9.7000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Percutaneous microwave ablation of HCC: comparison between 100 and 150 W technology systems.\",\"authors\":\"Carolina Lanza, Salvatore Alessio Angileri, Pierpaolo Biondetti, Andrea Coppola, Francesco Ricapito, Velio Ascenti, Gaetano Amato, Giuseppe Pellegrino, Lucilla Violetta Sciacqua, Andrea Vanzulli, Serena Carriero, Massimo Venturini, Anna Maria Ierardi, Gianpaolo Carrafiello\",\"doi\":\"10.1007/s11547-024-01927-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To evaluate the differences in efficacy and safety between the 100 and 150 W percutaneous microwave ablation (MWA) systems in the treatment of hepatocellular carcinoma (HCC).</p><p><strong>Methods: </strong>We retrospectively reviewed all patients who underwent percutaneous MWA (Emprint™ HP Ablation System, Medtronic) between January 2021 and May 2023. We divided the cohort into two groups: Group 1, treated with MWA at 100 W power system, and Group 2, treated with 150 W one. Effectiveness was defined as the absence of residual disease at 1-month CT follow-up; safety was defined as the absence of grade II-VI complications.</p><p><strong>Results: </strong>A total of 135 HCC nodules were treated with MWA in 87 patients with a median age of 66 ± 10 years: 76 procedures in 42 patients were carried out in group 1, while 59 procedures in 45 patients in group 2. Cases treated with 150 W had a shorter ablation time (p: 0.002; mean 227.37 ± 92.5 vs 180.51 ± 75.6 s (100 vs 150 W)) and a larger ablation volume (p 0.008; mean 13,920.0 ± 10,723.2 vs 21,241.4 ± 18,374.7 mm<sup>3</sup> (100 vs 150 W)), and a major effectiveness at 1-month CT follow-up (p: 0.013). A higher rate of complications (grade II and III) was observed in Group 2 (p < 0.001).</p><p><strong>Conclusions: </strong>In conclusion, these preliminary results showed a good correlation between intended-to-treat area and ablation volume and intended-to-treat area and ablation time for both Groups. A minor ablation time, and major ablation volume, but also a higher incidence of complications was observed in 150 W Group.</p>\",\"PeriodicalId\":20817,\"journal\":{\"name\":\"Radiologia Medica\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":9.7000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiologia Medica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11547-024-01927-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiologia Medica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11547-024-01927-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
目的：评估 100 W 和 150 W 经皮微波消融（MWA）系统在治疗肝细胞癌（HCC）方面的疗效和安全性差异：我们对2021年1月至2023年5月期间接受经皮微波消融术（Emprint™ HP消融系统，美敦力公司）的所有患者进行了回顾性研究。我们将患者分为两组：第 1 组使用功率为 100 W 的 MWA 系统进行治疗，第 2 组使用功率为 150 W 的 MWA 系统进行治疗。疗效的定义是在1个月的CT随访中无残留病灶；安全性的定义是无II-VI级并发症：87名患者共135个HCC结节接受了MWA治疗，中位年龄为66±10岁：第一组有42名患者接受了76次治疗，第二组有45名患者接受了59次治疗。使用 150 瓦功率治疗的病例消融时间较短（P：消融体积更大（P：0.008；平均 13,920.0 ± 10,723.2 vs 21,241.4 ± 18,374.7 mm3（100 W vs 150 W）），CT 随访 1 个月时疗效显著（P：0.013）。第 2 组的并发症（II 级和 III 级）发生率较高（P：0.013）：总之，这些初步结果表明，两组的预定治疗面积和消融量以及预定治疗面积和消融时间之间存在良好的相关性。150 瓦组的消融时间较短，消融量较大，但并发症发生率较高。
Percutaneous microwave ablation of HCC: comparison between 100 and 150 W technology systems.
Purpose: To evaluate the differences in efficacy and safety between the 100 and 150 W percutaneous microwave ablation (MWA) systems in the treatment of hepatocellular carcinoma (HCC).
Methods: We retrospectively reviewed all patients who underwent percutaneous MWA (Emprint™ HP Ablation System, Medtronic) between January 2021 and May 2023. We divided the cohort into two groups: Group 1, treated with MWA at 100 W power system, and Group 2, treated with 150 W one. Effectiveness was defined as the absence of residual disease at 1-month CT follow-up; safety was defined as the absence of grade II-VI complications.
Results: A total of 135 HCC nodules were treated with MWA in 87 patients with a median age of 66 ± 10 years: 76 procedures in 42 patients were carried out in group 1, while 59 procedures in 45 patients in group 2. Cases treated with 150 W had a shorter ablation time (p: 0.002; mean 227.37 ± 92.5 vs 180.51 ± 75.6 s (100 vs 150 W)) and a larger ablation volume (p 0.008; mean 13,920.0 ± 10,723.2 vs 21,241.4 ± 18,374.7 mm3 (100 vs 150 W)), and a major effectiveness at 1-month CT follow-up (p: 0.013). A higher rate of complications (grade II and III) was observed in Group 2 (p < 0.001).
Conclusions: In conclusion, these preliminary results showed a good correlation between intended-to-treat area and ablation volume and intended-to-treat area and ablation time for both Groups. A minor ablation time, and major ablation volume, but also a higher incidence of complications was observed in 150 W Group.
期刊介绍：
Felice Perussia founded La radiologia medica in 1914. It is a peer-reviewed journal and serves as the official journal of the Italian Society of Medical and Interventional Radiology (SIRM). The primary purpose of the journal is to disseminate information related to Radiology, especially advancements in diagnostic imaging and related disciplines. La radiologia medica welcomes original research on both fundamental and clinical aspects of modern radiology, with a particular focus on diagnostic and interventional imaging techniques. It also covers topics such as radiotherapy, nuclear medicine, radiobiology, health physics, and artificial intelligence in the context of clinical implications. The journal includes various types of contributions such as original articles, review articles, editorials, short reports, and letters to the editor. With an esteemed Editorial Board and a selection of insightful reports, the journal is an indispensable resource for radiologists and professionals in related fields. Ultimately, La radiologia medica aims to serve as a platform for international collaboration and knowledge sharing within the radiological community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
